by Jeremy S. Abramson, MD, MMSc; Brad Kahl, MD; and Matthew J. Matasar, MD
The classification of high-risk diffuse large B-cell lymphoma (DLBCL) is evolving to include more biologic and genetic markers. The treatment of pa......READ MORE
by Jeremy S. Abramson, MD, MMSc; Brad Kahl, MD; and Matthew J. Matasar, MD
Chimeric antigen receptor (CAR) T-cell therapy is a newer, potentially curative treatment when used after 2 or more lines of systemic therapy in re......READ MORE
by Jeremy S. Abramson, MD, MMSc; Brad Kahl, MD; and Matthew J. Matasar, MD
The expanding armamentarium for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is allowing patients to have more options for treatme......READ MORE
by Jeremy S. Abramson, MD, MMSc; Brad Kahl, MD; and Matthew J. Matasar, MD
Several newer therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are now available, and other agents that are under invest......READ MORE
The optimal management of double-hit relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) continues to be a challenge, with limited data t......READ MORE
Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who do not proceed to autologous hematopoietic stem cell transplantatio......READ MORE
